Compugen Ltd (CGEN)
NASDAQ:CGEN
CGEN Stock Chart & Stats
$2.06
-$0.04(-2.19%)
At close: 4:00 PM EST
$2.06
-$0.04(-2.19%)
Day’s Range― - ―
52-Week Range$1.13 - $2.38
Previous CloseN/A
Volume276.40K
Average Volume (3M)283.91K
Market Cap
$194.78M
Enterprise Value$107.14M
Total Cash (Recent Filing)$145.64M
Total Debt (Recent Filing)$2.96M
Price to Earnings (P/E)4.0
Beta1.34
Next Earnings
May 18, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.60
Shares Outstanding94,553,190
10 Day Avg. Volume231,873
30 Day Avg. Volume283,909
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.39
Price to Sales (P/S)1.96
P/FCF Ratio4.56
Enterprise Value/Market Cap0.55
Enterprise Value/Revenue1.47
Enterprise Value/Gross Profit1.69
Enterprise Value/Ebitda3.21
Forecast
1Y Price Target
$4.00Price Target Upside94.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.21
Revenue Forecast (FY)$17.93M
Bulls Say, Bears Say
Bulls Say
Balance Sheet And Cash RunwayThe significant upfront payment for partial royalty rights strengthened Compugen's balance sheet and extended cash runway, reducing near-term dilution risk and supporting continued program advancement.
Discovery Platform AdvantageThe Unigen artificial intelligence and machine learning platform provides a differentiated discovery approach that could accelerate creation of new assets and attract further high-value partnerships.
Late-stage Clinical DevelopmentAstraZeneca's leadership of a broad late-stage clinical program for rilvegostomig signals confidence in the asset and could substantially boost commercial prospects if pivotal studies produce positive outcomes.
Bears Say
Revenue Concentration And SustainabilityDependence on a one-time upfront payment for a meaningful share of revenue raises concerns about sustainable cash generation and long-term financial stability.
TIGIT Class Clinical RiskPersistent negative sentiment toward the TIGIT drug class and prior program failures increase clinical and commercial risk for TIGIT-related candidates.
Compugen News
CGEN FAQ
What was Compugen Ltd’s price range in the past 12 months?
Compugen Ltd lowest stock price was $1.13 and its highest was $2.38 in the past 12 months.
What is Compugen Ltd’s market cap?
Compugen Ltd’s market cap is $194.78M.
When is Compugen Ltd’s upcoming earnings report date?
Compugen Ltd’s upcoming earnings report date is May 18, 2026 which is in 52 days.
How were Compugen Ltd’s earnings last quarter?
Compugen Ltd released its earnings results on Mar 02, 2026. The company reported $0.6 earnings per share for the quarter, beating the consensus estimate of -$0.075 by $0.675.
Is Compugen Ltd overvalued?
According to Wall Street analysts Compugen Ltd’s price is currently Undervalued.
Does Compugen Ltd pay dividends?
Compugen Ltd does not currently pay dividends.
What is Compugen Ltd’s EPS estimate?
Compugen Ltd’s EPS estimate is -0.07.
How many shares outstanding does Compugen Ltd have?
Compugen Ltd has 94,553,190 shares outstanding.
What happened to Compugen Ltd’s price movement after its last earnings report?
Compugen Ltd reported an EPS of $0.6 in its last earnings report, beating expectations of -$0.075. Following the earnings report the stock price went up 24.309%.
Which hedge fund is a major shareholder of Compugen Ltd?
Currently, no hedge funds are holding shares in CGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Compugen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (94.17% Upside)
$4.00 (94.17% Upside)
Blogger Sentiment
Bearish
CGEN Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.64%
12-Months-Change
Fundamentals
Return on Equity
55.68%
Trailing 12-Months
Asset Growth
36.42%
Trailing 12-Months
Company Description
Compugen Ltd
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
CGEN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed materially positive financial and operational developments: a meaningful non‑dilutive capital infusion ($65M) that extended the cash runway into 2029, a large year‑over‑year revenue and profitability swing driven by partner upfronts, validated partnerships with AstraZeneca and Gilead, and clinical progress for COM701 and GS‑0321 (trial initiations, conference presentations, and global site expansion). Offsetting these positives are risks and limitations: revenues are lumpy and dependent on partner milestones, a delay moved the COM701 interim analysis to Q1 2027 (though sites are now open), and program timing and data disclosure remain partly controlled by partners. Overall, highlights (cash runway, profitability, partnerships, clinical advancement) outweigh the lowlights (timing, revenue concentration, partner dependence), supporting a positive outlook but with continued execution and partner‑dependent milestones being key.View all CGEN earnings summariesCGEN Stock 12 Month Forecast
Average Price Target
$4.00
▲(94.17% Upside)
Technical Analysis
Ownership Overview
―
Insiders
3.71% Mutual Funds
7.90% Other Institutional Investors
86.36% Public Companies and
Individual Investors